Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments addressing high unmet medical needs [2] - The company’s marketed products include TONMYA, the first new treatment for fibromyalgia in over 15 years, and acute migraine products Zembrace Symtouch and Tosymra [2] - Tonix is advancing a pipeline that includes investigational drugs for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis, and kidney transplant rejection [2] Upcoming Presentation - Seth Lederman, MD, the CEO of Tonix, will present at BIO-Europe Spring 2026 on March 24, 2026, from 1:30 to 1:45 p.m. WET in Lisbon, Portugal [1][2] - The presentation will take place in Presentation Theatre A [2] Product Development - TONMYA is currently being evaluated in Phase 2 clinical trials for its potential in treating major depressive disorder and acute stress disorder [2] - TNX-2900 is Phase 2 ready for treating Prader-Willi syndrome, a rare disease [2] - The immunology pipeline includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection [2]

Core Insights - Kuaishou has officially opened a channel for prescription drug sales, targeting specific categories and recruiting qualified pharmaceutical merchants, marking a significant expansion into the pharmaceutical sector after OTC drugs, medical devices, and health products [2] - The entry into prescription drugs is selective, focusing on chronic disease areas such as cardiovascular, respiratory, and digestive systems, which have stable online demand and high user engagement [2] - The timing aligns with the upcoming implementation of the revised Drug Administration Law in February 2026, which will regulate third-party platforms for drug transactions, establishing clear responsibilities for platform operators [3] Industry Context - The Chinese pharmaceutical e-commerce landscape is dominated by giants like Alibaba Health and JD Health in B2C, and Meituan and Ele.me in O2O instant retail, creating a competitive environment for new entrants like Kuaishou [3] - The consumption logic of pharmaceuticals contrasts with the impulse-driven model of interest-based e-commerce, posing challenges for Kuaishou in gaining traction in this market [3] Governance Challenges - Kuaishou faces ongoing governance issues within its pharmaceutical vertical, with concerns over gray market activities disguised as health education, leading to the sale of counterfeit products [4] - The platform is actively working to combat these issues, having reported significant efforts in 2024 to tackle black and gray market activities, including collaboration with law enforcement to address related crimes [4] Market Opportunities - The fastest-growing category within prescription drugs is chronic disease management, which aligns well with Kuaishou's strengths in short video and live streaming for patient education [4] - Pharmaceutical companies are considering establishing official flagship stores on Kuaishou, not just for sales but to enhance brand recognition and engage with targeted users through content [5] - Kuaishou's entry into prescription drugs may redefine the dynamics of user engagement, shifting from a traditional model of "goods finding people" to "people finding goods" as users may regularly purchase medications based on content engagement [5]

Core Viewpoint - Merck Animal Health has received FDA approval for an expanded label for BRAVECTO® QUANTUM, allowing for the treatment and control of specific tick species in dogs for an extended duration of 12 months [1] Group 1: Product Information - The product BRAVECTO® QUANTUM is an extended-release injectable suspension containing fluralaner [1] - The updated indication specifically targets the Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) [1] Group 2: Regulatory Approval - The approval was granted by the U.S. Food and Drug Administration (FDA) [1]

Core Insights - The First Trust Morningstar Dividend Leaders Index Fund (FDL) is a passively managed ETF that focuses on high-yielding U.S. stocks with stable and sustainable dividends, tracking an index that emphasizes dividend consistency and earnings coverage [4][6][32] Fund Structure and Strategy - FDL tracks the Morningstar Dividend Leaders Index, which starts with the Morningstar US Market Index and applies three filters: exclusion of non-qualifying income stocks, screening for dividend consistency, and ensuring sustainability of dividends based on earnings [5][6] - The remaining stocks are ranked by dividend yield to select the top 100, with portfolio weights based on the total dollar value of expected dividends rather than yield [8][10] - As of now, FDL holds 86 stocks, with a maximum of 100, and has approximately $7.1 billion in assets under management (AUM) [9][10] Portfolio Composition - The top ten holdings account for nearly 60% of the portfolio, with Exxon Mobil, Chevron, and Verizon being the largest positions [10][11] - Sector exposure is heavily weighted towards Energy (28.5%), followed by Health Care (16.95%) and Consumer Defensive (13.54%), indicating a significant tilt away from sectors like Technology [12][10] Performance Metrics - FDL has a trailing P/E ratio of about 14x, which is below the category average of approximately 17x, and has shown less volatility compared to the S&P 500 [13][19] - The fund has historically underperformed the broader U.S. market by about 1.5% per year since inception, with a maximum drawdown of -12.14% recorded between February and October 2023 [20][19] Market Sensitivity - FDL tends to lag during growth-led market rallies, particularly when technology stocks dominate, but it outperformed the broader market by approximately 25% in 2022 when the focus shifted towards income and dividends [23][24] - Rising interest rates may pose challenges as they compete with dividend stocks, but FDL's low valuation and high current yield could mitigate some of these effects [24] Comparison with Peers - FDL's closest peers include the iShares Core High Dividend ETF (HDV) and the WisdomTree U.S. High Dividend Fund (DHS), with FDL having a higher expense ratio of 0.43% compared to HDV's 0.08% [25][26] - FDL has outperformed its two closest peers over the past decade, despite having a higher turnover rate of 46-58%, which can lead to more taxable capital gains distributions [31][29]

Core Insights - Talphera, Inc. will host a virtual investor and analyst event on March 23, 2026, to discuss Niyad® for continuous renal replacement therapy (CRRT) [1] - The event will feature principal investigators from the NEPHRO CRRT study, which evaluates Niyad's efficacy [1][2] Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings [9] - The lead product candidate, Niyad, is a lyophilized formulation of nafamostat, which has received Breakthrough Device Designation from the FDA [9] Product and Study Details - Nafamostat is a broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, and potential antiviral properties, used in CRRT for over 30 years in Japan and South Korea [2] - Niyad aims to serve as a regional anticoagulant for patients who cannot tolerate heparin or are at risk of bleeding, addressing limitations of current anticoagulants [2] - The NEPHRO CRRT study is a prospective, double-blinded trial enrolling 70 adult patients in U.S. ICUs, focusing on the mean post-filter activated clotting time as the primary endpoint [7] Expert Involvement - Blaithin McMahon, PhD, and Joao Teixeira, MD, are principal investigators with extensive backgrounds in nephrology and critical care, contributing to the study's credibility [4][5]

InMed Pharmaceuticals Conference Call Summary Company Overview - **Company Name**: InMed Pharmaceuticals - **Ticker Symbol**: INM (NasdaqCM) - **Industry**: Drug Development - **Focus**: Targeting CB1 and CB2 receptors for neurodegenerative diseases, particularly Alzheimer's disease [2][3] Key Drug Candidates - **INM-901**: - Targets neural inflammation in Alzheimer's disease - Orally bioavailable, disease-modifying therapeutic - Can cross the blood-brain barrier [2][3] - **INM-089**: - Focuses on dry age-related macular degeneration (AMD) - Aims to stop disease progression and potentially reverse damage [22][24] - **INM-755**: - Targets chronic severe itch in epidermolysis bullosa - Phase 2A studies showed meaningful improvement in itch scores [27][28] Alzheimer's Disease Insights - **Neuroinflammation**: - Emerging research indicates it may be a precursor to Alzheimer's, rather than a result [6][10] - INM-901 aims to modulate inflammation by targeting CB1 and CB2 receptors [7][8] - **Preclinical Results**: - INM-901 showed neuroprotective effects, reduced inflammation, and improved cognitive outcomes in animal models [9][20] - Significant reduction in pro-inflammatory markers observed [19][20] Dry AMD Insights - **Market Opportunity**: - Dry AMD has a larger patient population and high unmet medical need [22] - INM-089 demonstrated preservation of retinal function in preclinical studies [25][26] Financial Snapshot - **Cash Position**: Approximately $7 million as of December 31, sufficient to reach Q4 of the current year [31] - **Market Capitalization**: Around $4 million, considered low for the technology and team in place [31][32] Development Timeline - **INM-901**: - Targeting pre-IND meeting with the FDA in Q3 2026 - Clinical trials expected to begin in 2027 [32][33] - **INM-089**: - Similar timeline, potentially a quarter behind INM-901 [33] Intellectual Property - **Patent Portfolio**: - Broad patents covering the class of compounds and their modifications - Positioned for both in-house development and potential out-licensing opportunities [41][42] Strategic Initiatives - Focus on strategic partnerships and co-development opportunities to accelerate product development [34][33] Conclusion - InMed Pharmaceuticals is positioned with promising drug candidates targeting significant medical needs in neurodegenerative diseases and ocular conditions. The company is actively pursuing regulatory pathways and strategic partnerships to enhance its development capabilities and market presence [34][32]

Core Viewpoint - The TrumpRx website, aimed at reducing prescription drug prices for Americans, is not consistently offering lower prices compared to those in the UK, contradicting President Trump's claims of significant price reductions [1][4]. Group 1: Price Comparisons - Approximately one-third of the 54 drugs listed on the TrumpRx website are cheaper in the UK, with price differences ranging from 67% to 82% lower for specific medications such as Xeljanz, Farxiga, and GSK inhalers [3][10]. - The TrumpRx pricing for obesity drugs like Zepbound and Wegovy has been significantly reduced to between $149 and $350 per month, down from over $1,000, reflecting a substantial discount [10][11]. Group 2: Economic Impact on Drugmakers - Drugmakers have mixed views on the financial impact of the most-favored-nation pricing, with some companies like Novo Nordisk warning of potential profit drops of up to 13% by 2026 due to lower negotiated prices [7][15]. - Companies such as Novartis and Roche believe the impact will be immaterial, while Johnson & Johnson estimates a financial hit in the "hundreds of millions of dollars," which is relatively minor compared to their overall pharmaceutical sales exceeding $60 billion [15][16]. Group 3: Healthcare System Dynamics - The TrumpRx initiative is described as a "big... really expensive coupon book," primarily benefiting cash-paying consumers rather than those with insurance, which complicates the affordability issue for most Americans [5][6][14]. - The UK's National Health Service (NHS) employs a structured pricing system for medicines, which contrasts with the more variable pricing under TrumpRx, leading to higher cash prices for Americans compared to government-negotiated prices in the UK [12][13].

Core Insights - The study from Washington University School of Medicine highlights the cardiovascular risks associated with discontinuing GLP-1 medications for Type 2 diabetes, indicating that stopping these drugs can lead to increased risks of heart attack, stroke, and death [2][3][4]. Group 1: Study Findings - The research followed over 333,000 adults with diabetes, primarily using Novo Nordisk's Ozempic, over three years [3]. - Patients who remained on GLP-1s for three years experienced an 18% reduction in cardiovascular risk [7]. - Quitting GLP-1s for as little as six months increased cardiovascular risk by 4%, while a two-year gap raised the risk to 22% compared to continuous use [7]. Group 2: Drug Benefits and Risks - GLP-1s provide significant benefits beyond weight loss, including reductions in cholesterol, blood pressure, insulin resistance, and inflammation, along with cardiovascular protection [3][4]. - The study emphasizes that the cardiovascular protection gained from GLP-1s takes years to build but can be lost in a much shorter time frame [3]. Group 3: Discontinuation Issues - High discontinuation rates for GLP-1s range from 36% to 81%, driven by access issues and side effects like nausea and vomiting [5]. - The need for long-term treatment adherence is critical, as providers and patients must recognize the consequences of stopping the medication [5][6]. - Drugmakers are working on next-generation treatments that aim to maintain efficacy while reducing side effects [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx between August 3, 2023, and December 26, 2025, to discuss their legal rights [1][3]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the reliability of information on setrusumab's effects and downplayed the risks of the Phase III Orbit study failing to achieve significant results [5]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [6]. - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [7][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [4][6]. Group 1: Legal Investigation - The law firm is reminding investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Aquestive [4]. - The complaint alleges that Aquestive and its executives made false or misleading statements and failed to disclose the true state of the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [6]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price fell by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [7]. Group 3: Investor Participation - The court-appointed lead plaintiff is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation on behalf of the class [8]. - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].